2021 American Transplant Congress
Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: Phase 3 IMAGINE Study Design
*Purpose: Chronic active antibody-mediated rejection (CAMR) is a major cause of allograft loss with no approved drugs for its treatment. Currently, off-label regimens recommended by…2021 American Transplant Congress
Machine Perfusion of Kidney Grafts in Simultaneous Liver Kidney Transplantation: National Trends and Outcomes
*Purpose: In this study we analyze the SRTR liver data set to determine the trends in machine perfusion of kidney grafts prior to SLK and…2021 American Transplant Congress
HLA Allele Association with Recurrent Iga Nephropathy After Kidney Transplantation
Transplant, Washington University, Saint Louis, MO
*Purpose: IgA nephropathy is one of the most common glomerulonephritis after kidney transplantation. The association of IgA nephropathy recurrence with recipient HLA typing is not…2021 American Transplant Congress
Impact of Covid-19 in Transplant Care: Attitudes, Feeling and Behaviors of Liver, and Kidney Pre and Post Transplant Patients
Beth Israel Deaconess Medical Center, Boston, MA
*Purpose: The SARS-CoV-2(COVID-19) pandemic poses unique challenges for transplant patients, which may impact their attitudes, emotions and behaviors associated with transplant care. This study surveys…2021 American Transplant Congress
Defining the Characteristics and Graft Outcomes of Kidney Transplant Recipients with Elevated Plasma Oxalate Level Not Due to Primary Hyperoxaluria
*Purpose: Patients with elevated systemic oxalate burden due to enteric etiologies are at increased risk for calcium oxalate deposition causing ESRD. The objective of this…2021 American Transplant Congress
Comprehensive Utilization of HCV Viremic and Non-Viremic Donor Livers and Kidneys into HCV-negative Patients
Transplant Institute, Loma Linda University Health, San Bernardino, CA
*Purpose: We report our experience on virologic and graft outcomes of HCV-negative patients transplanted with HCV NAT+ (viremic) and HCV Ab+/NAT- (non-viremic) livers and kidneys…2021 American Transplant Congress
Development of Novel Multivariable Logistic Regression Model for Predicting Acute Kidney Injury After Liver Transplantation
Organ Transplant Center,, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
*Purpose: Acute kidney injury (AKI) is a common early complication after liver transplantation, but there are no related predictive tools or models at present. The…2021 American Transplant Congress
A Fresh Look at Urbanicity and Its Impact on Additions to the Kidney and Liver Transplant Wait Lists
General Surgery, Vanderbilt University Medical Center, Nashville, TN
*Purpose: Our aim is to examine the collective effects of social determinants of health (SDH) on kidney and liver wait list additions in the United…2021 American Transplant Congress
A Significantly Shorter Waiting Time to Subsequent Kidney Transplant After Liver Transplant by Using Safety Net Policy
Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
*Purpose: In August 2017, a new simultaneous liver-kidney transplant (SLK) allocation policy and medical eligibility criteria were introduced. These criteria aim to avoid dual organ…2021 American Transplant Congress
Is There a Role for Donor-Specific Antibody Testing in Simultaneous Liver-Kidney Transplantation? A Single Center Analysis of Outcomes
University of Southern California, Los Angeles, CA
*Purpose: Simultaneous liver-kidney transplantation (SLKT) has grown exponentially since its conception in the 1960’s. The role for donor specific antibody (DSA) testing in SLKT is…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 24
- Next Page »